Resistance to 5-aza-2'-deoxycytidine in genic regions compared to non-genic repetitive sequences

Journal of Reproduction and Development

Volumn 56, Issue 1, 2010, Pages 86-93

  Lim, Hui Wen ^a   Iwatani, Misa ^a   Hattori, Naoko ^a   Tanaka, Satoshi ^a   Yagi, Shintaro ^a   Shiota, Kunio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

5 aza 2' deoxycytidine; Decitabine; DNA methylation; Epigenetics; Histone modification

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CIRCADIAN RHYTHM SIGNALING PROTEIN; CLU PROTEIN, MOUSE; CLUSTERIN; DIPEPTIDASE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; HOMEODOMAIN PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PER1 PROTEIN, MOUSE; SALL3 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL; ARTICLE; CELL STRAIN 3T3; CPG ISLAND; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOUSE; NUCLEOTIDE REPEAT;

3T3 CELLS; ANIMALS; AZACITIDINE; CLUSTERIN; CPG ISLANDS; DIPEPTIDASES; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HOMEODOMAIN PROTEINS; MICE; OCTAMER TRANSCRIPTION FACTOR-3; PERIOD CIRCADIAN PROTEINS; REPETITIVE SEQUENCES, NUCLEIC ACID; TRANSCRIPTION FACTORS;

EID: 77649299465     PISSN: 09168818     EISSN: 13484400     Source Type: Journal    
DOI: 10.1262/jrd.20247     Document Type: Article

References (51)

1. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-6875.
2. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793-797.
3. Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 2003; 17: 910-918.
4. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem 1982; 257: 2041-2048.
5. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004; 24: 1270-1278.
6. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003; 63: 4984-4989.
7. Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res 2008; 647: 44-51.
8. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, Lubbert M. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-2964.
9. Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C, Otterson GA. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene 2001; 20: 7787-7796.
10. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-1640.
11. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008; 112: 2341-2351.
12. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 2003; 97: 1242-1247.
13. Oki Y, Aoki E, Issa JP. Decitabine-bedside to bench. Crit Rev Oncol Hematol 2007; 61: 140-152.
14. Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420: 520-562.
15. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32: e38.
16. Jeong KS, Lee S. Estimating the total mouse DNA methylation according to the B1 repetitive elements. Biochem Biophys Res Commun 2005; 335: 1211-1216.
17. Ji W, Hernandez R, Zhang XY, Qu GZ, Frady A, Varela M, Ehrlich M. DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutat Res 1997; 379: 33-41.
18. Weber M, Schubeler D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr Opin Cell Biol 2007; 19: 273-280.
19. Shiota K, Kogo Y, Ohgane J, Imamura T, Urano A, Nishino K, Tanaka S, Hattori N. Epigenetic marks by DNA methylation specific to stem, germ and somatic cells in mice. Genes Cells 2002; 7: 961-969.
20. Hattori N, Nishino K, Ko YG, Hattori N, Ohgane J, Tanaka S, Shiota K. Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells. J Biol Chem 2004; 279: 17063-17069.
21. Ohgane J, Wakayama T, Senda S, Yamazaki Y, Inoue K, Ogura A, Marh J, Tanaka S, Yanagimachi R, Shiota K. The Sall3 locus is an epigenetic hotspot of aberrant DNA methylation associated with placentomegaly of cloned mice. Genes Cells 2004; 9: 253-260.
22. Liang G, Chan MF, Tomigahara Y, Tsai YC, Gonzales FA, Li E, Laird PW, Jones PA. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002; 22: 480-491.
23. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 2003; 23: 5594-5605.
24. Hattori N, Abe T, Hattori N, Suzuki M, Matsuyama T, Yoshida S, Li E, Shiota K. Preference of DNA methyltransferases for CpG islands in mouse embryonic stem cells. Genome Res 2004; 14: 1733-1740.
25. Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr Opin Cell Biol 2002; 14: 286-298.
26. Vermaak D, Ahmad K, Henikoff S. Maintenance of chromatin states: an open-andshut case. Curr Opin Cell Biol 2003; 15: 266-274.
27. Ikegami K, Iwatani M, Suzuki M, Tachibana M, Shinkai Y, Tanaka S, Greally JM, Yagi S, Hattori N, Shiota K. Genome-wide and locus-specific DNA hypomethylation in G9a deficient mouse embryonic stem cells. Genes Cells 2007; 1: 1-11.
28. Ikegami K, Ohgane J, Tanaka S, Yagi S, Shiota K. Interplay between DNA methylation, histone modification and chromatin remodeling in stem cells and during development. Int J Dev Biol 2009; 53: 203-214.
29. Joseph A, Mitchell AR, Miller OJ. The organization of the mouse satellite DNA at centromeres. Exp Cell Res 1989; 183: 494-500.
30. Davidson S, Crowther P, Radley J, Woodcock D. Cytotoxicity of 5-aza-2'-deoxycytidine in a mammalian cell system. Eur J Cancer 1992; 28: 362-368.
31. Rosemblit N, Chen CL. Regulators for the rat clusterin gene: DNA methylation and cis-acting regulatory elements. J Mol Endocrinol 1994; 13: 69-76.
32. McIver CM, Lloyd JM, Hewett PJ, Hardingham JE. Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma. Cancer Lett 2004; 209: 67-74.
33. Stoger R, Kubicka P, Liu CG, Kafri T, Razin A, Cedar H Barlow DP. Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal. Cell 1993; 73: 61-71.
34. Jackson JP, Lindroth AM, Cao X, Jacobsen SE. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 2002; 416: 556-560.
35. Tamaru H, Zhang X, McMillen D, Singh PB, Nakayama J, Grewal SI, Allis CD, Cheng X, Selker EU. Trimethylated lysine 9 of histone H3 is a mark for DNA methylation in Neurospora crassa. Nat Genet 2003; 34: 75-79.
36. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998; 395: 89-93.
37. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW. 5-Aza-2'-deoxycytidine- mediated reductions in G9A histone methyltransferase and histone H3 K9 dimethylation levels are linked to tumor suppressor gene reactivation. Oncogene 2007; 26: 77-90.
38. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res 2002; 62: 6456-6461.
39. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002; 62: 7213-7218.
40. Fuks F, Hurd PJ, Deplus R, Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 2003; 31: 2305-2312.
41. Li H, Rauch T, Chen ZX, Szabo PE, Riggs AD, Pfeifer GP. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem 2006; 281: 19489-19500.
42. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-191.
43. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389.
44. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG., Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000; 404: 1003-1007.
45. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-556.
46. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, Schreiber SL, Mellor J, Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature 2002; 419: 407-411.
47. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006; 66: 3541-3549.
48. Brinkman AB, Roelofsen T, Pennings S, Martens J, Jenuwein T, Stunnenberg HG. Histone modification patterns associated with the human X chromosome. EMBO Rep 2006; 7: 628-634.
49. Kim A, Kiefer C, Dean A. Distinctive signatures of histone methylation in transcribed coding and noncoding human β-globin sequences. Mol Cell Biol 2007; 27: 1271-1279.
50. Vakoc C, Mandat S, Olenchock B, Blobel GA. Histone H3 lysine 9 methylation and HP1γ are associated with transcription elongation through mammalian chromatin. Mol Cell 2005; 19: 381-391.
51. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91: 11797-11801.